Ausencia de interferencias por anticuerpos heterófilos en la cuantificación de Troponina I Cardíaca, en pacientes con insuficiencia renal crónica terminal en tratamiento de hemodiálisis

Carmen Cecilia Almonacid; Jorge Cantillo Turbay; Janneth Carolina Quintana; Lorena Astrid Quiroga; Yolima Andrea Parrado

doi:10.22490/24629448.1048

Absence of interferences for heterophilic antibodies in the quantification de cardiacTroponin I, in patients with terminal chronic renal inadequacy in hemodialysis treatment

Ausencia de interferencias por anticuerpos heterófilos en la cuantificación de Troponina I Cardíaca, en pacientes con insuficiencia renal crónica terminal en tratamiento de hemodiálisis

Open | Download

PDF (Spanish) FLIP HTML (Spanish)

Issue

Vol. 1 No. 1 (2003)

Section

Artículo Original

How to Cite

Almonacid, C. C., Cantillo Turbay, J., Quintana, J. C., Quiroga, L. A., & Parrado, Y. A. (2014). Absence of interferences for heterophilic antibodies in the quantification de cardiacTroponin I, in patients with terminal chronic renal inadequacy in hemodialysis treatment. NOVA, 1(1). https://doi.org/10.22490/24629448.1048

DOI

https://doi.org/10.22490/24629448.1048

Dimensions

PlumX

license

NOVA by http://www.unicolmayor.edu.co/publicaciones/index.php/nova is distributed under a license creative commons non comertial-atribution-withoutderive 4.0 international.

Furthermore, the authors keep their property intellectual rights over the articles.

Carmen Cecilia Almonacid

Universidad Colegio Mayor de Cundinamarca. Bogotá, Colombia.

Jorge Cantillo Turbay

Servicio de Terapia Renal Hospital Universitario Clínica San Rafael. Bogotá, Colombia.

Janneth Carolina Quintana

Universidad Colegio Mayor de Cundinamarca. Bogotá, Colombia.

Lorena Astrid Quiroga

Universidad Colegio Mayor de Cundinamarca. Bogotá, Colombia.

Yolima Andrea Parrado

Universidad Colegio Mayor de Cundinamarca. Bogotá, Colombia.

Show authors biography

Troponin I

Uremic cardiopatic

Heterophilic antibodies

The present study seeks to value the behavior of the addition of the blocking reagent of heterophilic antibodies (HBR), in the cardiac Troponin I quantification in patient with terminal chronicle renal inadequacy subjected to hemodialysis treatment. To each one of 70 patients with IRCt in hemodialysis treatment in the San Rafael University Hospital of Bogot·, they were taken a sample of serum and one of plasm heparanized in the pre dialysis, in which the TnIc concentrations were quantified with and without HBR addition, by means of the enzimoinmunoassay Axsym. The statistical test of Wilcoxon was used. The TnIc values in plasms and serums with and without the HBR addition didn't show significant differences (0.113 and 0.666 respectively), so much in the total of the patients as in those with chronic cardiac illness. Not having found differences in the TnIc values with and without HBR it takes us to think of the absence of heterophilic antibodies or in that the blocking reagent HBR doesn't have action in this population of patients.

Article visits 170 | PDF visits 92

Downloads

Download data is not yet available.

Parfrey P, et al. The clinical epidemiology of cardiac disease in chronic renal failure. Journal of the American Society of Nephrology 1999;10:1606-15.
Mac Laurin M, et al. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialys patients without ischemic heart disease: Evidence of cardiac Troponin T expression in skeletal muscle. Clin Chem 1997;43(6):976-82.
Montgomery J, et al. Comparison of serum and EDTA plasma for CK-MB, myoglobin and cardiac Troponin I (cTnI) using the Beckman Access immunoassay Analyzer. Clin Chem 1998;44(6):A141.
Datta P. Bayer Corporation, Diagnostic Division. ACS 180 cardiac Troponin I (cTnI) and myoglobin assays are free from rheumatoid factor interference. Clin Chem 1999;45(6):A136.
Wayand D, et al. Cardiac Troponin T and I in End- Stage Renal Failure. Clin Chem 2000;46:1345-50.
Granier C, et al. Human cardiac Troponin I: Precise identification of antigenic epitopes and prediction of secondary structure. Clin Chem 1998;44(3):487-93.
Coudry L, et al. The Troponins. Arch Intern Med 1998;158:1173-80.
Panteghini M. Acute Coronary Syndrome. Chest 2002;122(4):1428-35.
Willging S, et al. Specificity of cardiac Troponins I and T in Renal Disease. Clin Chem Lab Med 1998;36(2):87-92.
Hohnadel D, et al. Alternative samples for Troponin I testing. Clin Chem 1998;44(6):A120.
Fitzmaurice T, et al. False increase for cardiac Troponin I with heterophilic antibodies. Clin Chem 1998;44(10):2212-4.
Qinwei S, et al. Degradation of cardia Troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem 1999;45(7):1018-25.
Gerhardt W, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000;46:817-21.
Almonacid C, et al. Comportamiento y valor pronóstico de la Troponina I cardiaca en Insuficiencia Renal Crónica: un estudio en 69 pacientes de hemodiálisis. Acta Médica Colombiana 2002;27(5):306.
Hartnert J, et al. Congestive hart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney International 1995;47:884-90.
Stoffel M, et al. Troponin I is a better prognostic parameter of cardiovascular events in asymtomatic patients on haemodialysis than troponin T. Nephrol Dial Transplant 2000;15:1259-60.
Labugger R, et al. Extensive Troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000;102:1221-6.
Katrukha A, et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem 1998;44(12):2433- 40.
-------------------------------------------------------------------------------
DOI: http://dx.doi.org/10.22490/24629448.1048